CHRISTINE BOYET: Open Payments
NPI 1922571967 · FRANKLINTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,427 in 100 payments from 25 companies in 2025. Trend: 2023 $1,741 · 2024 $1,950 · 2025 $2,427
Food & beverage: $2,427
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $401 |
| AstraZeneca Pharmaceuticals LP | 8 | $355 |
| Lilly USA, LLC | 10 | $233 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $197 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $163 |
| Supernus Pharmaceuticals, Inc. | 10 | $157 |
| Novo Nordisk Inc | 9 | $136 |
| Astellas Pharma US Inc | 6 | $130 |
| Madrigal Pharmaceuticals | 1 | $112 |
| Ardelyx, Inc. | 1 | $89 |
Products named: BREZTRI, VRAYLAR, CAPLYTA, XIFAXAN, Qelbree, FARXIGA, Veozah, MOUNJARO.
Industry payments across LA — which companies pay providers there.
